News Bellerophon Therapeutics, Inc.

Equities

BLPH

US0787713009

Market Closed - OTC Markets Other stock markets 09:30:00 2024-05-10 EDT			5-day change	1st Jan Change
0.0562 ^USD	0.00%		-10.08%	+51.89%

05-02	North American Morning Briefing : Stock Futures -2-	DJ
04-25	North American Morning Briefing : More Tech -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures -2-	05-02	DJ
North American Morning Briefing : More Tech -2-	04-25	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors	03-04	CI
Bellerophon Therapeutics, Inc. Announces Executive Changes	11-21	CI
Bellerophon Therapeutics, Inc. Announces Executive Changes	11-21	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	11-20	DJ
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index	23-10-18	CI
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing	23-10-17	MT
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board	23-10-13	CI
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index	23-10-13	CI
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	23-07-28	MT
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director	23-07-14	CI
Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	23-06-29	PU
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023	23-06-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bellerophon Therapeutics, Inc.

Equities

BLPH

US0787713009

Summary

Filters